Honeywell And Recipharm To Speed Development Of Inhalers With A Near-Zero Global Warming Potential Propellant

MORRIS PLAINS, N.J. and STOCKHOLM, August 17, 2023 – Honeywell (Nasdaq: HON) and global contract development and manufacturing organization (CDMO) Recipharm have today announced a commercial partnership that will speed the development of pressurized metered dose inhalers (pMDIs) that use Honeywell’s near-zero global warming potential (GWP) propellant.